Search Result

Results for "

human PPARδ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) ERK (1) Isotope-Labeled Compounds (2) NO Synthase (1) PPAR (18) Reference Standards (3)
By Research Areas:	Cancer (4) Cardiovascular Disease (9) Inflammation/Immunology (7) Metabolic Disease (12)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13861

GW7647 20+ Cited Publications	PPAR	Cardiovascular Disease
GW7647 is a potent PPARα agonist, with EC₅₀s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-16995

Pirinixic acid Maximum Cited Publications 33 Publications Verification Wy-14643	PPAR	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-B0637

Bezafibrate 10+ Cited Publications BM15075	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human* PPARα, PPARγ and *PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ*, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-13928

GW0742 15+ Cited Publications GW610742	PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 is a potent PPARβ and *PPARδ* agonist, with an IC₅₀ of 1 nM for human *PPARδ* in binding assay, and EC₅₀s of 1 nM, 1.1 μM and 2 μM for human *PPARδ, PPARα, and PPAR*γ, respectively.

HY-114263

NXT629 4 Publications Verification	PPAR	Cancer
NXT629 is a potent, selective, and competitive *PPAR-α* antagonist, with an IC₅₀ of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC₅₀s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively . NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models .

HY-168376

9(10)-Nitrooleate 9(10)-Nitrated oleic acid	PPAR ERK Akt NO Synthase	Metabolic Disease Inflammation/Immunology
9 (10)-Nitrooleate (9(10)-Nitrated oleic acid) is an endogenous lipid signaling mediator with vasoprotective effects. 9 (10)-Nitrooleate enhances enzymatic activity and improves nitric oxide bioavailability by inducing phosphorylation of Akt and ERK1/2, regulating the multi-site phosphorylation status of eNOS and optimizing its interaction with Hsp90. 9 (10)-Nitrooleate also activates PPARα, PPARδ and PPARγ receptors, thereby regulating adipogenesis, glucose uptake and inflammation-related gene expression, and exhibits immunosuppressive effects by inhibiting neutrophil migration and cytokine secretion. 9 (10)-Nitrooleate is widely used in studies of sepsis and related inflammatory diseases .

HY-114739

MA-0204	PPAR	Metabolic Disease
MA-0204 is a potent, highly selective and orally available peroxisome proliferator activated receptor δ (PPARδ) modulator with EC₅₀s of 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively. Potential treatment for Duchene Muscular Dystrophy (DMD) .

HY-B0637S

Bezafibrate-d6	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-13928R

GW0742 (Standard) GW610742 (Standard)	PPAR Reference Standards	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 (Standard) is the analytical standard of GW0742. This product is intended for research and analytical applications. GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

HY-162963

PPARδ agonist 11	PPAR	Inflammation/Immunology
PPARδ agonist 11 (Compound 11) is a selective agonist for *PPARδ* with an EC₅₀ of 20 nM. PPARδ agonist 11 reduces the levels of nitrite oxide (NO), proinflammatory cytokines TNFα and IL-6 in LPS (HY-D1056)-stimulated RAW264.7 cell, and exhibits anti-inflammatory efficacy via NF-κB pathway. PPARδ agonist 11 exhibits good stability in human liver microsomes and plasma. PPARδ agonist 11 ameliorates Carrageenan (HY-125474)-induced foot edema .

HY-B0637S1

Bezafibrate-d4 BM15075-d₄	Isotope-Labeled Compounds PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637R

Bezafibrate (Standard) BM15075 (Standard)	Reference Standards PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate (Standard) is the analytical standard of Bezafibrate. This product is intended for research and analytical applications. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human* PPARα, PPARγ and *PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ*, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637S2

Bezafibrate-13C6 BM15075-¹³C₆	Isotope-Labeled Compounds PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate- ¹³C₆ (BM15075- ¹³C₆) is ¹³C labeled Bezafibrate. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human* PPARα, PPARγ and *PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ*, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-170581

PPARγ/δ modulator 2	PPAR	Metabolic Disease
PPARγ/δ modulator 2 (Compound 3h) is a PPARγ agonist and *PPARδ* antagonist. The K_i values for PPARγ and *PPARδ* are 2.8 μM and 43 nM, respectively. PPARγ/δ modulator 2 significantly enhances the production of Adiponectin and promotes adipogenic differentiation of human bone marrow mesenchymal stem cells (hBM-MSCs). PPARγ/δ modulator 2 can be used in the study of metabolic disorders associated with hypoadiponectinemia .

HY-13861R

GW7647 (Standard)	PPAR	Cardiovascular Disease
GW7647 (Standard) is the analytical standard of GW7647. This product is intended for research and analytical applications. GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-162123

PPARα/δ agonist 2	PPAR	Inflammation/Immunology
PPARα/δ agonist 2 (compound 14) is a potent PPARα and *PPARδ* agonist with EC₅₀s of 3255 nM and 1475 nM for human PPARα and PPARβ/δ, respectively. PPARα/δ agonist 2 shows anti-inflammatory effects .

HY-16995R

Pirinixic acid (Standard) Wy-14643 (Standard)	PPAR Reference Standards	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Standard) is the analytical standard of Pirinixic acid. This product is intended for research and analytical applications. Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-182619

PPARα/δ antagonist-1	PPAR	Cancer
PPARα/δ antagonist-1 is an orally active, highly selective dual antagonist of PPARα/δ, with IC₅₀ values of 0.113 μM and 0.025 μM against human PPARα and *PPARδ, respectively. PPARα/δ antagonist-1 exhibits an excellent in vitro activity profile and preliminary efficacy in mouse tumor models. PPAR*α/δ antagonist-1 can be used in studies related to cancers (melanoma metastasis, ovarian cancer) .

Cat. No.	Product Name	Chemical Structure

HY-B0637S

Bezafibrate-d6
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637S1

Bezafibrate-d4
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637S2

Bezafibrate-13C6
Bezafibrate- ¹³C₆ (BM15075- ¹³C₆) is ¹³C labeled Bezafibrate. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human* PPARα, PPARγ and *PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ*, respectively; Bezafibrate is used as an hypolipidemic agent.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.